Slide 1: Q3 2016/17 Earnings presentation
Q3 2016/17 Earnings presentation Meet the Management, London 2017 Lars Rasmussen, President & CEO Anders Lonning Skovgaard, EVP & CFO
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 33% before one-off adjustment
Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 33% before one-off adjustment for Veterans Affairs Q3 Highlights Revenue growth +7% • Q3 organic growth of 8% (6% reported growth) Reported revenue (DKKm) +6% • Reported revenue in Q3 negatively Organic growth 11,548 +8% 10,942 affect
Slide 4: Timeline of SpeediCath patent litigations
Timeline of SpeediCath® patent litigations Injunction issued against Hollister Inc. and Teleflex Medical GmbH in the European Patent Regional Court Düsseldorf “Landgericht Office (EPO) Düsseldorf” Coloplast files an validates injunction against Coloplast’s Product: VaPro, VaPro Plus, VaPro Hollister
Slide 5: 9M organic growth of 7% with good performance across most business areas and geographies
9M organic growth of 7% with good performance across most business areas and geographies 9M 16/17 revenue by business area 9M 16/17 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm gr
Slide 6: Ostomy Care grew 7% organically in Q3 and continues to be driven by SenSura
Ostomy Care grew 7% organically in Q3 and continues to be driven by SenSura® range and Brava® accessories Performance Comments • 9M organic growth of 7% (6% reported growth). Q3 organic growth of 7% (8% reported growth) • The acquisition of Comfort Medical contributed 1% growth to revenue in Ostomy
Slide 7: Continence Care grew 10% in Q3 driven by SpeediCath intermittent catheters
Continence Care grew 10% in Q3 driven by SpeediCath® intermittent catheters and strong performance in the US Performance Comments • 9M organic sales growth of 8% (7% reported growth). Q3 organic growth of 10% (12% reported growth) • The acquisition of Comfort Medical contributed 2% growth to 12 reve
Slide 8: Urology Care grew 10% in Q3 driven by US sales of Altis slings and Titan penile implants
Urology Care grew 10% in Q3 driven by US sales of Altis® slings and Titan® penile implants Performance Comments • 9M organic growth of 11% (12% reported growth). Q3 organic growth of 10% • Growth in Q3 driven by the US and Europe 15 • Strong growth in sales of Altis® slings and Titan® penile implant
Slide 9: WC negatively impacted by price reforms in Greece and France and weak momentum in Emerging Markets
WC negatively impacted by price reforms in Greece and France and weak momentum in Emerging Markets Performance Comments • 9M organic sales growth of 0% for WSC (1% reported growth). Q3 organic growth for WSC of 1% 8 • 9M organic growth of 3% for Wound Care in isolation, and negative 1% 6 in Q3. Woun
Slide 10: 9M EBIT in constant currencies & before one-off adjustment for VA grew 9%
9M EBIT in constant currencies & before one-off adjustment for VA grew 9% corresponding to an EBIT margin of 33% Comments EBIT margin development • EBIT grew 4% to DKK 3,705m with a reported margin of 32% (33% in constant currencies, before one-off revenue adjustment) compared to 33% last year 32.9
Slide 11: FCF adjusted for Mesh settlements, acquisition of Comfort Medical and tax payments was in line with last year
FCF adjusted for Mesh settlements, acquisition of Comfort Medical and tax payments was in line with last year Performance Comments • Free cash flow was positive DKK 322m compared to positive DKK 27 1,643m in 9M 2015/16 26 • EBITDA DKK 201m higher than same period last year 22 20 20 20 4,023 • NWC-to
Slide 12: Updated financial guidance for 2016/17
Updated financial guidance for 2016/17 Guidance 16/17 Guidance 16/17 (DKK) Long term ambition Sales growth 7-8% (organic) ~6% from 7-8% 7-9% p.a. 33-34% (constant EBIT margin ~32% from ~33% +50-100 bps p.a. exchange rates) CAPEX (DKKm) ~700 4-5% of sales Tax rate ~23 Page 12
Slide 13: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C